https://www.selleckchem.com/products/rvx-208.html
At week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 milligrams (mean difference from placebo [95% confidence interval]) Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57, 1.88]) and (1.47 [0.80, 2.13], respectively), overall work impairment (-11.67 [-19.66, -3.69] and -11.75 [-19.93, -3.57], respectively) activity impairment (-10.42 [-16.37, -4.47] and -10.51 [-16.59, -4.43], respectively), physical component summary (2.07 [0.42, 3.72] and 1.91 [0.22, 3.59], respectivel
Like
Comment
Share
